Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax in Idiopathic Pulmonary Fibrosis
NCT05976217Phase 1Completed
- Sponsor
- University of Alabama at Birmingham
- Start
- Oct 2023
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of venetoclax in idiopathic pulmonary fibrosis (IPF), sponsored by University of Alabama at Birmingham. Primary endpoints: Number of participants with treatment-related adverse events as assessed by measuring liver function at 3 weeks and Number of participants with treatment-related adverse events as assessed by measuring blood counts at 3 weeks. Started Oct 2023; status: completed.
02
Drugs
venetoclax
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT05976217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05976217.